- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07937852
A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS)
A Multicenter, Single Arm, Open-label, Extension, Roll-over Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis
The primary purpose of this study is to evaluate the long-term safety of fenebrutinib in participants with MS who were previously enrolled in one of the eligible Roche-sponsored parent studies, including, but not limited to FENhance I (NCT04586010), FENhance II (NCT04586023), FENtrepid (NCT04544449), and FENopta (NCT05119569).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Studera Kontakt Backup
- Namn: Reference Study ID Number: CN45787 https://forpatients.roche.com/ No attachments to email below.
- Telefonnummer: 888-662-6728
- E-post: global-roche-genentech-trials@gene.com
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Previous eligibility and participation in the open-label extension (OLE) phase of an eligible Roche-sponsored parent study, where the participant is receiving fenebrutinib as an investigational medicinal product (IMP)
- Minimum of 24 weeks exposure to open-label fenebrutinib in parent study
- Ability and willingness to comply with all aspects of the protocol including completion of procedures, interviews, questionnaires, assessments for the duration of the study
Exclusion Criteria:
- Concurrent participation in any clinical trial (other than the parent study). Participants who withdrew from fenebrutinib treatment in their respective parent study should also be excluded
- Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required
- Chronic liver disease unless considered stable for >6 months
- Acute liver disease
- Cirrhosis (Child-Pugh Class A, B, or C)
- Gilbert's syndrome
- Aspartate aminotransferase (ALT) or alanine aminotransferase (AST) > 1.5 × upper limit of normal (ULN)
- Total bilirubin greater than 1.5 × ULN
- A "yes" on any item of the Suicidal Behavior section of the Columbia-Suicide Severity Rating Scale (C-SSRS) or significant risk of a suicide, in the investigator's judgment
Note: Other protocol-defined inclusion/exclusion criteria may apply
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Fenebrutinib
Participants receiving fenebrutinib in OLE of their parent study may be eligible for enrollment in this extension study. Participants will continue fenebrutinib treatment at the dosage and route of administration received at the time of rollover from the parent study. |
Fenebrutinib will be administered as per the schedule specified in the protocol.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Number of Participants With Adverse Events (AEs)
Tidsram: Up to approximately 2 years
|
Up to approximately 2 years
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Change in Expanded Disability Status Scale (EDSS) Score Over Time
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in 9-hole Peg Test (9-HPT) Over Time
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Timed 25-foot Walk Test (T25FWT) Over Time
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of Composite 24-week Confirmed Disability Progression (cCDP24)
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of 24-week Confirmed Disability Progression (CDP24)
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of Modified cCDP24
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of 24-week Confirmed Disability Improvement (CDI24)
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Number of New or Enlarging T2 Magnetic Resonance Imaging (MRI) Lesions
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Number of T1 Hypointense MRI Lesions
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Total Volume of T2 Lesions
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Total Volume of T1 Hypointense Lesions
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Total Brain Volume
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Annualized Relapse Rate (ARR) (for Relapsing Multiple Sclerosis [RMS] Participants Only)
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Patient-reported Outcome Measure Information System/Quality of Life in Neurological Disorders - Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a) Over Time
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Multiple Sclerosis Impact Scale - 29-item (MSIS-29), Version 2 Physical Scale Over Time
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in MSIS-29 Psychological Scale Over Time
Tidsram: Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Clinical Trials, Hoffmann-La Roche
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CN45787
- 2026-526037-26-00 (Ctis)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .